Dong-a Socio Holdings Co., Ltd. · KRX:000640
Dong-a Socio — Dong-A Pharmaceutical — Q1 2012 Earnings Presentation
30 slides from Dong-a Socio's earnings presentation, April 2012
Slide 1: Dong-A Pharmaceutical 1Q 2012 Performance Results
Dong-A Pharmaceutical 1Q 2012 Performance Results APRIL 2012 All of us at Dong-A are dedicated to buliding a heathler society for humanity. Thia philosophy encompasses the health and well- being of humankind as a whole as well as the environment and the vormy. Committed to building a healthier socie
Slide 2: Audit review and forward-looking statement notice
The business results for the 1st quarter of 2012, currently under audit review, are presented here for investors’ convenience. Hence, please be advised that some of their contents may be altered in the course of audit. This presentation may contain “forward-looking statement.” Forecasts and projecti
Slide 3: Agenda
I. Financial Performance (K-IFRS Separate) II. Performance by Division III. R&D Update Appendix 2
Slide 4: I. Financial Performance (K-IFRS Separate)
I, FINANCIAL PERFORMANCE (K-IFRS SEPARATE) DONG-A PHARM.
Slide 5: Sales and Operating Profit Margin
[KRW bil.] [KRW bil.] 14.4% 7.4% 7.4% 2.9% 4.0% -5.2% 218.6 230.7 218.6 210.2 1Q '11 1Q '12 4Q '11 1Q '12 Sales OPM 4
Slide 6: Cost ratios and operating profit margin
1Q ‘11 1Q '12 4Q '11 YoY QoQ Cost of Goods Sold Ratio 39.1% 48.9% 49.5% 9.8%p -0.6%p Operating Profit Margin 47.5% 44.7% 44.4% -2.9%p 0.3%p HR Related Cost per Sales 14.8% 11.9% 10.2% -2.8%p 1.7%p (Salary + Severance + Fringe Benefit) R&D Cost per Sales 8.4% 11.1% 8.7% 2.7%p 2.4%p (Reflected in SG&A
Slide 7: Major Financial Ratios
[KRW bil.] ‘11. 12 ‘12. 03 YoY Major Financial Ratios Total Asset 1,236.8 1,268.1 2.5% 75.7% 68.9% Cash 154.6 178.6 15.6% Liability to Equity Ratio 44.9% 143.6 141.7 38.0% Payable -1.3% Debt to Equity Ratio Inventory 120.4 127.9 6.3% 16.9% 20.2% Net Debt to Equity Ratio Total Liability 504.4 546.3 8
Slide 8: II. Performance by Division
Il. PERFORMANCE BY DIVISION DONG-A PHARM.
Slide 9: ETC sales
[KRW bil.] -13.9% -6.0% 125.1 114.5 107.7 1Q '11 1Q '12 4Q '11 8
Slide 10: ETC sales by product
[KRW bil.] -5.4% 22.1 21.0 -34.6% -23.1% 11.5 -31.5% 10.5 8.8 -28.3% 8.1 7.5 17.2% 35.0% 3.8% 6.8 -28.5% -44.3% 6.1 5.6 5.6 4.8 4.8 5.0 4.9 4.6 4.8 4.1 3.3 2.7 Stillen Plavitor Lipinon Opalmon Growtropin Talion Zydena Orodipine Gaster Cozartan 1Q '11 1Q '12 9
Slide 11: OTC sales: Other OTC and Bacchus
[KRW bil.] -2.9% 68.0 66.0 27.2% 51.9 11.8% 29.8 33.3 31.6% Other OTC 25.3 Bacchus -14.4% 38.2 23.1% 32.7 26.6 1Q '11 1Q '12 4Q '11 10
Slide 12: OTC sales by product
[KRW bil.] 23.1% 32.7 26.6 6.7% 54.5% 7.3 -0.7% 1.9% New 6.9 5.3 3.4 3.7 3.7 2.5 2.8 2.8 0.0 Bacchus Total Bacchus F Panpyrin Garglin Bigen Morning Care 1Q '11 1Q '12 11
Slide 13: Diagnostics and Medical Equipment
[KRW bil.] 25.2 -18.5% 20.6 14.2% 12.3 18.0 Diagnostics -22.7 % 9.5 31.2 % 7.3 Medical Equipment 12.9 -14.5 % 11.0 10.7 2.8 % 1Q '11 1Q '12 4Q '11 12
Slide 14: Medical equipment by product
[KRW bil.] -20.9% 6.5 5.1 19.8% -33.7% -6.7% -14.2% 2.4 2.3 2.0 1.5 1.3 1.2 1.3 1.1 Artificial Joint Blood Vessel Stent Prosthetic Heart Dental Implant Sphygmotonograph Valve & Surgical 1Q '11 1Q '12 Equipment 13
Slide 15: Export sales
[KRW bil.] 52.2% 76.0% 21.6 14.2 12.3 1Q '11 1Q '12 4Q '11 14
Slide 16: Export sales by product
[KRW bil.] 44.5% 5.7 350.8% 5.2 3.9 8.3% 3.3 221.0% 3.0 2.5 5.6% 8.7% 1.1 1.0 1.1 1.0 0.8 0.9 Cycloserine Growtropin Bacchus Terizidone Eporon Zydena 1Q '11 1Q '12 15
Slide 17: Export sales by country
[KRW bil.] 10.3% 4.8 615.2% 4.3 3.9 54.3% 3.3 2.7 347.8% New 90.9% 103.8% 1.9 1.6 1.5 1.5 0.8 0.7 0.6 0.4 0.0 India Brazil Japan Cambodia Russia Turkey S. Africa 1Q '11 1Q '12 16
Slide 18: III. R&D Update
Ill. R&D UPDATE DONG-A PHARM.
Slide 19: R&D pipeline: chemical NCE candidates
CODE TYPE MAJOR INDICATION DESCRIPTION STAGE NAME Phase 3 completed Erectile Dysfunction (US) Warner Chilcott Benign Prostatic Phase 2 planned (US) DA – 8159 Hyperplasia PDE-5 Inhibitor Warner Chilcott Under Phase 2 (EU) Portal Hypertension Dr. Falk Pulmonary Arterial Under Phase 2 (KR) Hypertension
Slide 20: R&D pipeline: phyto and bio candidates
MAJOR TYPE CODE NAME DESCRIPTION STAGE INDICATION Phyto DA-9801 Diabetic Neuropathy Herbal Extracts Under Phase 2 (KR) Infertility (Ovulation DA-3801 Recombinant FSH Under Phase 3 (KR) Induction) DA-3803 Infertility Recombinant hCG Under Phase 3 (KR) DA-3030 Diabetic Neuropathy G-CSF Phase 3 planned
Slide 21: R&D on Bio at Beginning Stage
R&D on Bio at Beginning Stage Biosimilar/better - DA-3811 (Gaucher Disease, Cerezyme Biosimilar) DA-3808 (Hemophilia A, Advate Biosimilar) DA-3880 (Anemia of Chronic Renal Failure, Aranesp Biosimilar) Antibody - DA-3111 (her2 Positive Breast Cancer, Herceptin Biosimilar) 20
Slide 22: Protein/Antibody development timeline
2013~2014 2015~2016 2017~ DA-3091* DA-3808 (PEGylated Exenatide) (Factor VIII) DA-3801 (rhFSH) - Diabetes - Hemophilia - Anovulation DA-3051** DA-3131 (Interferon ß) (Antibody) DA-3803 (rhCG) - Multiple Sclerosis - Cancer - Infertility (Brazil) DA -3111 DA-3607 (TRAIL) (Herceptin) DA-3031* - Brain T
Slide 23: Chemical/Phyto development timeline
2013~2014 2015~2016 2017~ DA-8159** - BPH (US, JP) DA-8159** DA-6034 - ED (US) - Dry Eye DA-7218** DA-1229 -MRSA (US) - Diabetes DA-8159** - PAH (EU) DA-8031 DA-6034 - Premature - Gastritis Ejaculation DA-9801 - Diabetic Neuropathy Chemical/ Phyto **Overseas 22
Slide 24: Appendix
L, DONG-A PHARM.
Slide 25: Quarterly balance sheet
[KRW bil.] 1Q ‘11 2Q ‘11 3Q ’11 4Q ‘11 1Q ‘12 Total Assets 1,137.8 1,150.7 1,195.0 1,236.8 1,268.1 Current Assets 403.4 416.1 458.9 466.2 496.7 Cash 146.8 144.1 188.3 154.6 178.6 Receivables 131.9 140.1 144.8 143.6 141.7 Inventories 118.5 115.6 109.7 120.4 127.9 Fixed Assets 734.4 734.6 736.1 770.6
Slide 26: Quarterly income statement
[KRW bil.] 1Q ‘11 2Q ‘11 3Q ‘11 4Q ‘11 2011 1Q ‘12 Sales 210.2 224.5 241.9 230.7 907.3 218.6 CoGS 82.3 93.0 113.7 114.2 403.3 106.9 Gross Profit 128.0 131.5 128.2 116.4 504.0 111.7 SG&A 99.9 104.1 98.8 102.4 405.2 97.6 Other Income 3.6 3.4 1.0 2.3 10.2 2.8 Other Loss 1.3 0.9 2.1 9.7 14.0 0.8 Operati
Slide 27: Sales by division
[KRW bil.] Division 1Q ‘11 2Q ‘11 3Q ‘11 4Q ‘11 2011 1Q ‘12 ETC Total 114.5 120.9 135.9 125.1 496.5 107.7 OTC Total 51.9 62.2 70.7 68.0 252.9 66.0 Bacchus 26.6 38.7 46.7 38.2 150.1 32.7 Other OTC 25.3 23.5 24.0 29.8 102.7 33.3 Medical Total 25.2 23.5 17.8 18.0 84.5 20.6 Medical Equipment 12.9 12.3 1
Slide 28: Sales by product
[KRW bil.] Products 1Q ‘11 2Q ‘11 3Q ‘11 4Q ‘11 2011 1Q ‘12 Stillen 22.1 21.9 21.0 23.2 88.1 21.0 Lipinon 11.5 11.7 11.3 11.5 45.9 7.5 Plavitor 10.5 11.7 10.5 11.4 44.1 8.1 Opalmon 8.8 9.7 9.7 8.7 37.0 6.1 Orodipine 6.8 7.0 6.1 6.3 26.3 4.9 Growtropin 4.8 4.8 6.0 5.4 21.0 5.6 Zydena 4.8 5.0 5.1 5.2
Slide 29: Sales by product (OTC)
[KRW bil.] Products 1Q ‘11 2Q ‘11 3Q ‘11 4Q ‘11 2011 1Q ‘12 Bacchus 26.6 38.7 46.7 38.2 150.1 32.7 Panpyrin 6.9 4.7 4.5 6.3 22.3 7.3 Bigen 3.7 3.7 4.0 3.5 14.9 3.7 Garglin 3.4 3.2 3.1 3.4 13.1 5.3 Morning Care 2.8 2.7 2.4 3.2 11.1 2.8 28
Slide 30: Thank you
—_—__— Thank you
Dong-A Pharmaceutical — Q1 2012 Earnings Presentation on 6ix